Thats what I think is happening..20% of float short.37 million shares outstanding..Albeit.good news from Canada we move 10 points higher
Im long but.serious good news needed to save this company
We have a 85% chance that not only do we get approval.They get bought out and use translarna for other nonsense mutations......200.00
The biotech will come raging back
I think PTCT has a product for un met needs and time is of the essence..I agree would like to see the approvals help those who need it most..Stock price should explode
All of them..So..Short squeeze buy out good news,hopefully all in the works
$ 35 to 50 on high end.....They will continue to make Billions and their money back in less than 5 years
I agree.I think once their combos start to take off with news,so will the stock.They can still be bought out by JNJ
or anybody else willing to pay the right price
In that deal, J&J acquired the rights to Achillion's HCV franchise, including ACH-3422, a drug that Achillion was hoping to use alongside ACH-3102 instead of Sovaldi in future trials.
Because J&J already has a strong HCV research program that includes the prior-generation therapy Incivek, the more recently-approved Olysio, as well as assets acquired when it bought Alios last year, all of which can be combined with Achillion's pipeline, investors may not want to count Achillion out just yet.
If J&J can craft a shorter-duration, next-generation HCV drug, Achillion could receive up to $1.1 billion in milestones and mid-teens to low-20s royalties on eventual sales. Because J&J also took a $225 million equity stake in Achillion at a price of $12.25 per share, Achillion's current $8.69 price and $1.02 billion market cap could ultimately be too low.
They are raking in billions with growth all over and soon to be all over the planet